Fig. 2: Patient selection and study treatment. | Nature Communications

Fig. 2: Patient selection and study treatment.

From: Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

Fig. 2

a Representative immunohistochemistry of paraffin-embedded ovarian cancers showing a range of FRα membrane expression on 10 to 95% of tumour cells. b FRα membrane expression for all enroled patients (mean ± SEM; dotted line represents the 5% expression threshold required for trial eligibility; n = 26). c The trial dosing schedule consisted of 6 weekly doses of MOv18 IgE, before first on-treatment tumour assessment. d Skin prick testing comprised histamine positive control [+], saline negative control [−] and MOv18 IgE solution. The result of this typical skin prick test was negative. e MOv18 IgE dose escalation, and number of patients treated in each cohort (*cohort 2 included 2 patients not evaluable for safety who did not receive intravenous dosing because of positive intradermal tests (see text); †a DLT occurred in these cohorts; ‡intra-patient dose escalation). Source data are provided as a Source Data file.

Back to article page